Pliant Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PLRX research report →
Companypliantrx.com
Pliant Therapeutics, Inc. , a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials.
- CEO
- Bernard Coulie
- IPO
- 2020
- Employees
- 171
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $74.30M
- P/E
- -0.66
- P/S
- 0.00
- P/B
- 0.45
- EV/EBITDA
- -0.74
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -59.06%
- ROIC
- -61.46%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-149,344,000 · 28.99%
- EPS
- $-2.43 · 29.97%
- Op Income
- $-150,073,000
- FCF YoY
- 19.23%
Performance & Tape
- 52W High
- $1.95
- 52W Low
- $1.09
- 50D MA
- $1.27
- 200D MA
- $1.40
- Beta
- 1.21
- Avg Volume
- 530.50K
Get TickerSpark's AI analysis on PLRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 17, 26 | Kuo Minnie | other | 150,000 |
| Apr 17, 26 | Kuo Minnie | other | 55,200 |
| Apr 17, 26 | Kuo Minnie | other | 40,000 |
| Apr 17, 26 | Kuo Minnie | sell | 150,000 |
| Apr 17, 26 | Kuo Minnie | sell | 40,000 |
| Apr 17, 26 | Kuo Minnie | sell | 55,200 |
| Apr 17, 26 | Cummings Keith Lamont | other | 124,000 |
| Apr 17, 26 | Cummings Keith Lamont | other | 113,300 |
| Apr 17, 26 | Cummings Keith Lamont | other | 110,500 |
| Apr 17, 26 | Cummings Keith Lamont | other | 76,200 |
Our PLRX Coverage
We haven't published any research on PLRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PLRX Report →